These results confirm previous studies that showed CRL4 to be dysregulated in ovarian cancer and, being that the ovarian cancer cell lines screened had unique mutational profiles, suggest that the observed sensitivity to CRL4 inhibition may be driven by lineage‐specific dependence rather than by specific genetic aberrations. Here, IL17RB is linked to ovarian cancer.